Mateon Therapeutics Inc. (MATN)
Stock Price:
$0.275 USD
-0.012 (-4.18%)
Updated Jul 31, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
24.64M |
| Revenue (ttm) |
340,855 |
| Net Income (ttm) |
-10.32M |
| Shares Out |
88.60M |
| EPS (ttm) |
-0.13 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 31, 2020 |
| Last Price |
$0.275 |
| Previous Close |
$0.287 |
| Change ($) |
-0.012 |
| Change (%) |
-4.18% |
| Day's Open |
0.290 |
| Day's Range |
0.250 - 0.295 |
| Day's Volume |
638,842 |
| 52-Week Range |
0.076 - 0.350 |
More Stats
| Market Cap |
24.64M |
| Enterprise Value |
25.57M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
88.60M |
| Float |
55.88M |
| EPS (basic) |
-0.13 |
| EPS (diluted) |
-0.13 |
| FCF / Share |
-0.02 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
662,753 |
| Short Ratio |
8.04 |
| Short % of Float |
2.50% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
72.29 |
| PB Ratio |
1.68 |
| Revenue |
340,855 |
| Operating Income |
-5.98M |
| Net Income |
-10.32M |
| Free Cash Flow |
-1.82M |
| Net Cash |
-931,871 |
| Net Cash / Share |
-0.01 |
| Gross Margin |
n/a |
| Operating Margin |
-1,755.43% |
| Profit Margin |
-3,027.60% |
| FCF Margin |
-534.02% |
| ROA |
-20.39% |
| ROE |
-117.42% |
| ROIC |
321.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
0.55
Current: $0.275
High
0.55
Target: 0.55
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | 0.10 | 0.16 | - | - |
| Revenue Growth | - | - | - | - | - | - | -39.1% | - | - | - |
| Gross Profit | - | - | - | - | - | - | 0.10 | 0.16 | - | - |
| Operating Income | -4.31 | -0.71 | -13.84 | -13.76 | -13.68 | -12.65 | -8.28 | -8.07 | -11.89 | -18.51 |
| Net Income | -6.64 | -0.71 | -13.81 | -13.65 | -13.65 | -12.65 | -8.28 | -8.08 | -9.65 | -23.77 |
| Shares Outstanding | 59.96 | 6.14 | 26.55 | 26.55 | 25.20 | 16.97 | 2.80 | 1.47 | 0.93 | 0.33 |
| Earnings Per Share | -0.11 | -0.12 | -0.52 | -0.51 | -0.54 | -0.75 | -4.67 | -5.48 | -10.37 | -71.60 |
| Operating Cash Flow | -2.28 | -0.24 | -10.93 | -15.24 | -11.93 | -12.15 | -7.00 | -8.34 | -11.78 | -20.43 |
| Capital Expenditures | - | - | - | - | -0.01 | -0.02 | -0.04 | -0.01 | - | - |
| Free Cash Flow | -2.28 | -0.24 | -10.93 | -15.24 | -11.94 | -12.17 | -7.04 | -8.34 | -11.78 | -20.42 |
| Cash & Equivalents | 0.08 | 0.00 | 1.12 | 12.05 | 27.29 | 30.03 | 7.01 | 4.97 | 9.99 | 4.68 |
| Total Debt | 0.96 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | -0.88 | 0.00 | 1.12 | 12.05 | 27.29 | 30.03 | 7.01 | 4.97 | 9.99 | 4.68 |
| Assets | 23.68 | 2.75 | 1.17 | 14.11 | 27.45 | 30.42 | 7.29 | 5.45 | 11.06 | 5.57 |
| Liabilities | 6.78 | 0.28 | 1.65 | 1.61 | 2.10 | 1.42 | 1.25 | 0.90 | 2.26 | 10.82 |
| Book Value | 16.90 | 2.46 | -0.48 | 12.50 | 25.35 | 29.00 | 6.04 | 4.55 | 8.80 | -5.26 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Mateon Therapeutics Inc. |
| Country |
United States |
| Employees |
13 |
| CEO |
Vuong Trieu |
Stock Information
| Ticker Symbol |
MATN |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: MATN |
| IPO Date |
August 26, 1993 |
Description
Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.